

CURRICULUM VITAE

<u>Name:</u>	Inbal Aida
<u>Place of Work:</u>	Rabin Medical Center, Beilinson Hospital
<u>Faculty:</u>	Medicine, Tel Aviv University
1970 – 1977	Graduated Medical School at Sackler School of Medicine, Tel-Aviv University, Israel
1985 – 1988	Research Fellowship, Harvard Medical School, Hematology Division, Brigham & Womens Hosp. Boston, MA, USA
1.2000	Associate Professor in Hematology, Tel-Aviv University, Sackler School of Medicine, Israel
1.2007	Professor in Hematology, Tel-Aviv University, Sackler School of Medicine, Israel
2002 - 2006	Head Division of Hematology, Sackler School of Medicine, Tel Aviv University
2002 - 2006	Acting Director Institute of Thrombosis and Hemostasis, Department of Hematology, Sheba Medical Center, Tel Hashomer
2005 - 2008	Chairman, Israeli Society of Thrombosis and Hemostasis
2006 - present	Director, Thrombosis & Hemostasis Unit, Beilinson Hospital, Rabin Medical Center, Petach Tiqva
09. 2009	Director Hematology Clinic, Beilinson Hospital
11. 2009	Head of Jose Henriques de Paiva Ferreira Thrombosis and Hemostasis Research Cathedra, Tel Aviv University

LIST OF PUBLICATIONS

1. Inbal A, Modan M, Many A. A retrospective study of patients with chronic myeloid leukemia diagnosed and treated at the Chaim Sheba Center during the years 1966-1976. Isr J Med Sci 14(12):1259,1978.

INBAL AIDA, M.D.**15.11.09**

2. Inbal A, van Dyk D, Jutrin I, Ravid M. Primary thrombocytopenia. *Harefuah* 100:278, 1981.
3. Van Dyk D, Inbal A, Kraus L, et al. The watery diarrhea syndrome with hypercalcemia – a symptomatic response to phosphate buffer. *Hepato Gastroenterol* 28:58-59, 1981.
4. Lang R, Inbal A, Jutrin I, Ravid M. Recurrent venous thrombosis – the sole manifestation of an occult myeloproliferative disease. *Isr J Med Sci* 18:705, 1982.
5. Avissar N, Inbal A, Rabisadeh E, Shaklai N. Interaction of spectrin with hemin disaggregate spectrin associations. *Biochem Intern* 8:113-120, 1984.
6. Inbal A, Akstein E, Barak I, Meytes D, Many A. Cyclic Leukocytosis and long survival in chronic myeloid leukemia. *Acta Haematol* 69:353, 1983.
7. Inbal A, Joshua H, Shaklai M. Autoerythrocyte sensitization – a case report and review of the literature. *Harefuah* 107:385-387, 1984.
8. Tamir R, Levin R, Inbal A, Heller I, Theodor E. High output cardiac failure in plasma cell leukemia. *Isr J Med Sci* 21:897, 1985.
9. Inbal A, Avidor I, Nemesh L, Shaklai M. Persistent lymphocytosis in sarcoidosis. An unusual feature in sarcoidosis. *Acta Haematol* 74:164, 1985.
10. Prokocimer A, Inbal A, Gelber M, Shohat B, Ben-Bassat M, Shaklai M. Hemophagocytosis simulating malignant histiocytosis, a terminal event of myelodysplastic syndrom. *Acta Haematol* 74:164-167, 1985.
11. Manor RS, Axer-Siegel R, Cohen S, Inbal A, Ben-Sira I. Bilateral anterior ischemic optic neuropathy, pseudoxantoma elasticum and platelet hyperaggregability. *Neuroophthalmol* 6:173, 1986.
12. Inbal A, Januszewicz E, Rabinowitz M, Shaklai M. A therapeutic trial with low dose cytarabine in myelodysplastic syndromes and acute leukemia. *Acta Haematol* 73:71, 1985.
13. Loscalzo J, Inbal A, Handin RI. Von Willebrand protein facilitates platelet incorporation in polymerizing fibrin. *J Clin Invest* 78:1112, 1986.
14. Inbal A, Modan M, Weitz Z, Lahav M, Shoenfeld N, Atsmon A, Shaklai M. Lymphocyte urosynthase in non-Hodgkin lymphoma. An indicator of disease extensiveness. *Cancer* 59:89, 1987.
15. Gutman H, Deutsch AA, Inbal A, Joshua H, Reiss R. Malignant lymphoma metastatic to the breast. *Breast Dis* 1:143, 1988.

INBAL AIDA, M.D.**15.11.09**

16. Mor F, Beigel M, Inbal A, Gorwen S, Wysenbeek A. Hepatic infarction in a patient with the lupus anticoagulant. *Art Rheum* 34:491, 1989.
17. Inbal A, Loscalzo J. Clycocalcin binding to von Willebrand factor absorbed onto collagen-coated or polystyrene surface. *Thromb Res* 56:347, 1989.
18. Ewenstein BM, Inbal A, Pober J, Handin RI. Molecular studies of von Willebrand's disease: Reduced von Willebrand factor biosynthesis, storage and release in endothelial cells derived from patients with type I von Willebrand's disease. *Blood* 75:1466-1472, 1990.
19. Inbal A, Handin R. Two Stu I polymorphisms in the 5' region of the von Willebrands factor (vWF) gene. *Nucl Acid Res* 18:4959, 1990.
20. Inbal A. Acquired von Willebrand disease, plasma cell dyscrasia, and angiodysplasia: more than a coincidence? *Isr J Med Sci* 26:518-519, 1990.
21. Inbal A. Haemarthrosis in patients with mild coagulation factor deficiency. *Blood Coag Fibrinol* 2:669-671, 1991.
22. Inbal A. von Willebrand factor and von Willebrand disease. *Harefuah* 120:478-482, 1991.
23. Inbal A, Kornbrot N, Zivelin A, Shaklai M, Seligsohn U. The Inheritance of type I and type III von Willebrand's disease in Israel: Linkage analysis, carrier detection and prenatal diagnosis using three intragenic restriction fragment length polymorphisms. *Blood Coag Fibrinol* 3:73-83, 1992.
24. Inbal A, Seligsohn U, Kornbort N, Brenner B, Harrison P, Randi A, Rabinowitz I, Sadler JE. Characterization of three mutations causing von Willebrand disease type IIA in five unrelated families. *Thromb Haemost* 67:618-622, 1992.
25. Wilbourn B, Harrison P, Lawrie A, Leroy F, Rowley M, Bevan D, Inbal A, Savidge G. Unique expression of von Willebrand factor by type IIA von Willebrand's disease endothelial cells. *Br J Haematol* 81:401-406, 1992.
26. Hodak E, Trattner A, David M, Kornbort N, Modan B, Lurie H, Laurie A, Harrison P, Sandbank M, Inbal A. Quantitative and qualitative assessment of plasma von Willebrand factor in classical Kaposi sarcoma. *J Amer Acad Dermatol* 28:217-221, 1993.
27. Blickstein D, Inbal A. Gene therapy: Science fiction or reality. *Harefuah* 124:784-787, 1993. Bairey O, Inbal A. Treatment of bleeding disorders by desmopressin. *Harefuah* 125:105-107, 1993.
28. Inbal A, Handin E. Two Taq I Polymorphisms in the 5' region of the von Willebrand factor gene. *Nucl Acid Res* 17:10143, 1989.

INBAL AIDA, M.D.**15.11.09**

29. Blickstein D, Shaklai M, Inbal A. Warfarin antagonism by avocado. *Lancet* 337:914-915, 1991. Blickstein D, Inbal A. Gene therapy: Science fiction or reality. *Harefuah* 124:784-787, 1993.
30. Bairey O, Inbal A. Treatment of bleeding disorders by desmopressin. *Harefuah* 125:105-107, 1993.
31. Inbal A, Englander T, Kornbort N, Randi AM, Castman G, Mannucci PM, Sadler JE. Identification of three candidate mutations causing IIA von Willebrand disease using a rapid non-radioactive allele specific hybridization method. *Blood* 82:830-836, 1993.
32. Inbal A, Blickstein D, Kornbort N, Brenner B, Martinowitz U, Epstein D. Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders. *Blood Coagul Fibrinol* 4:599-604, 1993.
33. Inbal A, Kornbrot N, Harrison P. Randi AM, Sadler JE. Effect of type IIB von Willebrand disease mutation Arg (545) Cys on platelet glycoprotein Ib binding. Studies with recombinant von Willebrand factor. *Thromb Haemost* 70:1058-1062, 1993.
34. Shmueli H, Pitlik SD, Inbal A, Rosenfeld JB. Pelger-Huet anomaly mimicking shift to the left. *Netherlands J Med* 432:168-170, 1993.
35. Inbal A, Shaklai M, Avissar N, Kuritzky A, Schejter A, Ben-David E, Shanske S, Garty B. Myopathy, lactic acidosis and sideroblastic anemia: A new syndrome. *Amer J Clin Genet* 55:272-278, 1995
36. Inbal A. Acquired abnormalities of coagulation: Factors to consider in patients with unexpected bleeding. *Isr Med Sci* 31:448-449, 1995.
37. Inbal A, Kornbrot N, Mannucci PM, Sadler JE. Very low frequency of "Normandy type: mutations among type 1 von Willebrand disease families. *Thromb Haemost* 73:324, 1995.
38. Englander T, Lattuada A, Mannucci PM, Sadler JE, Inbal A. Analysis Arg834Gln and Val902Glu Type 2A von Willebrand disease mutations. Studies with recombinant von Willebrand factor and correlation with patient characteristics. *Blood* 87:2788-2794, 1996.
39. Inbal A, Bank I, Zivelin A, Varon D, Dardik R, Shapiro R, Rosenthal E, Shenkman B, Gitel S, Seligsohn U. Acquired von Willebrand disease in a patient with angiodysplasia resulting from immune-mediated clearance of von Willebrand factor. *Br J Haematol* 96:179-182, 1997
40. Inbal A, Kenet G, Zivelin A, Yermiyahu T, Tamari H, Gitel S, Eshel G, Duchemin J, Aiach M, Seligsohn U. Purpura fulminans induced by

INBAL AIDA, M.D.**15.11.09**

- disseminated intravascular coagulation following infection in 2 unrelated children with double heterozygosity for factor V Leiden and protein S deficiency. *Thromb Haemost* 77:1086-1089, 1997
41. Inbal A, Yee VC, Kornbrot N, Zivelin A, Brenner B, Seligsohn U. Factor XIII deficiency due to a Leu660Pro mutation in the factor XIII subunit-A gene in three unrelated Palestinian Arab families. *Thromb Haemost* 77:1062-1067, 1997.
 42. Gurevitz O, Goldfarb A, Hod H, Feldman M, Shenkman B, Varon D, Eldar M, Inbal A. Recombinant von Willebrand factor fragment Arg545Cys inhibits platelet aggregation and enhances thrombolysis with rtPA in a rabbit thrombosis model. *Arterioscler Thromb Vasc Biol* 18:200-207, 1998.
 43. Inbal A. S-nitrosoderivative of a recombinant fragment of von Willebrand factor (S-nitroso-AR545C) : A unique antithrombotic agent. *Isr Med Assoc J* 1:290-291, 1999.
 45. Salomon O, Steinberg DM, Zivelin A, Gitel S, Dardik R, Rosenberg N, Berliner S, Inbal A, Many A, Lubetsky A, Varon D, Martinowitz U, Seligsohn U. Single and combined prothrombotic factors in pateints with idiopathic venous thromboembolism: prevalence and risk assessment. *Arterioscler Thromb Vasc Biol* 19:511-518, 1999.
 46. Lubetsky A, Schulman S, Varon D, Martinowitz U, Kenet G, Gitel S, Inbal A. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate P™) in patients with von Willebrand disease. *Thromb Haemost* 81:229-233, 1999.
 47. Inbal A, Freimark D, Modan B, Chetrit A, Hod H, Rosenberg N, Dardik R, Baron Z, Seligsohn U. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. *Blood* 93:2186-2197, 1999.
 48. Kenet G, Freedman JE, Michelson AD, Brand N, Loscalzo J, Inbal A. Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke. *Arterioscler Thromb Vasc Biol* 19:2017-2023, 1999.
 49. Zivelin A, Gitel S, Griffin JH, Xu X, Fernandez JA, Martinowitz U, Cohen Y, Halkin H, Seligsohn U, Inbal A. Extensive venous and arterial thrombosis induced by a specific inhibitor to activated protein C: A new mechanism for activated protein C resistance. *Blood* 94:895-901, 1999.
 50. Inbal A, Gurevitz O, Eskaraev R, Feldman M, Varon D, Tamarin I, Eldar M, Loscalzo J. Unique antiplatelet effects of a novel S-nitrosoderivative of a recombinant fragment of von Willebrand factor, AR545C: In vitro and ex vivo inhibition of platelet function. *Blood* 94:1693-1700, 1999.

INBAL AIDA, M.D.**15.11.09**

51. Dardik R, Varon D, Savion N, Eskaraev R, Tamarin I, Inbal A. Recombinant fragment of von Willebrand factor AR545C prevents platelet adhesion to thrombin-treated endothelial cells under flow by inhibiting thrombin-induced platelet activation. *Br J Haematol* 109:512-518, 2000.
52. Kenet G, Sadetzki S, Murad H, Martinowitz U, Rosenberg N, Gitel S, Rechavi G, Inbal A. Factor V Leiden and antophospholipid antibodies are significant risk factors for ischemic stroke in children. *Stroke* 31:1283-1288, 2000.
53. Gurevitz O, Skutelsky E, Eldar M, Tamarin I, Shenkman B, Eskaraev R, Varon D, Castel D, Loscalzo J, Inbal A. S-nitrosoderivative of a recombinant fragment of von Willebrand factor (S-nitroso-AR545C) inhibits thrombus formation in guinea pig carotid artery thrombosis model. *Thromb Haemost* 84:912-917, 2000.
54. Loscalzo J, Freedman J, Inbal A, Keaney JF Jr, Michelson AD, Vita JA. Nitric oxide insufficiency and arterial thrombosis. *Trans Am Clin Climatol Assoc* 111:158-53, 2000.
55. Salomon O, Rosenberg N, Zivelin A, Steinberg DM, Kornbrot N, Dardik R, Inbal A, Seligsohn U. Methionine syntase A2756G and methylenetetrahydrofolate reductase A1298C polymorphisms are not risk factors of idiopathic venous thromboembolism. *HematolJ* 2:38-41, 2001.
56. Luboshitz J, Lubetsky A, Schliamser L, Kotler A, Tamarin I, Inbal A. Pharmacokinetic studies with FVIII/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndrome. *Thromb Haemost* 85:806-9, 2001.
57. Hardy B, Indjtia L, Rodionov G, Raiter A, Inbal A. Treatment with BAT monoclonal antibody decreases tumor burden in a murine model of leukemia/lymphoma. *Int J Oncol* 19:897-902, 2001.
58. Streifler JY, Rosenberg N, Chetrit A, Eskaraev R, Sela BA, Dardik R, Zivelin A, Ravid B, Davidson J, Selighson U, Inbal A. Cerebrovascular events in patients with significant stenosis of the carotid artery are associated with hyperhomocysteinemia and platelet antigen 1 (Leu33Pro) polymorphisms. *Stroke* 32:2753-2758, 2001.
59. Rosenberg N, Zivelin A, Chetrit A, Dardik R, Kornbrot N, Inbal A. Effects of platelet membrane glycoprotein polymorphisms on the risk of myocardial infarction in young males. *Isr Med Assoc J* 4:411-414, 2002.
60. Dulitzky M, Cohen SB, Inbal A, Seidman DS, Soriano D, Lidor A, Mashiach S, Rabinovici J. Increased prevalence of thrombophilia among women with severe ovarian hyperstimulation syndrome. *Fertil Steril* 77:463-467, 2002.
61. Lubetsky A, Martinowitz U, Luboshitz J, Kenet G, Keller N, Tamarin I, Aida Inbal. Efficacy and Safety of a Factor VIII - Von Willebrand Factor Concentrate

INBAL AIDA, M.D.**15.11.09**

- 8Y: Stability, Bacteriological Safety, Pharmacokinetic Analysis and Clinical Experience. *Hemophilia* 8:622-628, 2002.
62. Carp H, Dolitzky M, Tur-Kaspa I, Inbal A. Hereditary thrombophilias are not associated with a decreased live birth rate in women with recurrent miscarriage. *Fertil Steril* 78:58-62, 2002.
 63. Dardik R, Shenkman B, Tamarin I, Eskaraev R, Harsfalvi J, Inbal A. Factor XIII mediates adhesion of platelets to endothelial cells through $\alpha v\beta 3$ and glycoprotein IIb/IIIa integrins. *Thrombosis Research* 105:317-323, 2002.
 64. Carp H, Salomon O, Seidman D, Dardik R, Rosenberg N, Inbal A. Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss. *Hum Reprod* 17:1633-1637, 2002.
 65. Inbal A. Management of Thrombosis during Pregnancy. Editorial. *Isr Med Assoc J* 4:813-14, 2002.
 66. Inbal A, Muszbek L. Coagulation factor deficiencies and pregnancy loss. *Semin Thromb Haemost* 29:171-174, 2003
 67. Inbal A, Kenet G. Pregnancy and surgical procedure in patients with factor XIII deficiency. *Biomed Prog* 16:69-71, 2003.
 68. Carp H, Dolitzky M, Inbal A. Thromboprophylaxis Improves The Live Birth Rate In Women With Consecutive Recurrent Miscarriages And Hereditary Thrombophilia. *J Thromb Haemost* 1:433-438, 2003.
 69. M. Klerk, P. Verhoef, R. Clarke, HJ Blom, FJ Kok, EG Schouten EG and the MTHFR Studies Collaboration Group (Abbate R, Marcucci R, Samani NJ, Anderson JL, Zebrack JS, Ardissino D, Morlini FM, van Bockxmeer FM, Brownrig L, Chambers J, Kooner JS, Genest J, Rozen R, Ferrer-Antunes C, Palmeiro A, Fernandez-Arcas N, Reyes-Engel A, Folsom AR, Fowkes FGR, Lee AJ, Gemmati D, Scapoli GL, Girelli D, Corrocher R, Gulec S, Hopkins PN, Inbal A, Seligsohn U, Kluijtmans LAJ, Jukema JW, Kozich V, Janosikova B, Ma J, Stampfer MJ, Malinow MR, Ashfield-Watt PAL, Clark ZE, Meisel C, Stangl K, Graham IM, Morita H, Nagai R, Nakai K, Yamakawa-Kobayashi K, Hamaguchi H, Gaziano M, Schwartz SM, Siscovick DS, Silberberg JS, Szczeklik A, Domagala Teresa B, Tanis BC, Rosendaal FM, Thogersen AM, Nilsson TK, Todesco L, Litynsky P, Tokgozoglu SL, Tsai MY, Hanson NQ, Rimm FB, Verhoeff BJ, Trip MD. MTHFR 677>T polymorphisms and risk of coronary heart disease: A meta-analysis. *JAMA* 288:2023-2032, 2002.
 70. Shenkman B, Inbal A, Tamarin I, Lubetsky A, Savion N, Varon D. Diagnosis of thrombotic thrombocytopenic purpura based on modulation by patient plasma of normal platelet adhesion under flow condition. *Br J Haematol* 120:597-604, 2003.
 71. Dardik R, Solomon A, Loscalzo J, Eskaraev R, Bialik A Inbal A. Novel proangiogenic effect of Factor XIII (FXIII) mediated by suppression of

INBAL AIDA, M.D.**15.11.09**

- thrombospondin1 expression (TSP-1). *Arterioscler Thromb Vasc Biol* 23:1472-1477, 2003.
72. Carp H, Dardik R, Lubetsky A, Eskaraev R, Rosenthal E, Inbal A. Prevalence of circulating procoagulant microparticles in women with recurrent miscarriage: A case controlled study. *Hum Reprod* 19:191-5, 2004.
 73. Casas K, Bykhovskaya Y, Mengesha E, Huiying Yang DW, Taylor K, Inbal A, Fischel-Ghodsian N. Gene responsible for mitochondrial myopathy and sideroblastic anemia (MSA) maps to chromosome 12q24.33. *Am J Med Genet* 127:44-49. 2004.
 74. Inbal A, Muszbek L, Lubetsky A, Katona E, Levi I, Karpati L, Nagler A. Platelets but not monocytes contribute to the plasma levels of factor XIII of subunit A in patients undergoing autologous peripheral blood stem cell transplantation. *Blood Coagul Fibrinol* 15:249-253, 2004.
 75. Bykhovskaya Y, Casas K, Mengesha E, Inbal A, Fischel-Ghodsian N. Missense mutation in pseudouridine synthase (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA). *Am J Hum Genet* 74:1303-1308. 2004.
 76. Inbal A, Lubetsky A, Shimoni A, Dardik R, Sela BA, Eskaraev R, Levi I, Shem-Tov N, Nagler A. Assessment of the Coagulation Profile in Hemato-Oncological Patients Receiving ATG Based Conditioning Treatment for Allogeneic Stem Cell Transplantation – a Randomized Controlled Study. *Bone Marrow Transplant* 34:459-463, 2004.
 77. Vysokovsky A, Saxena R, Landau M, Zivelin A, Eskaraev R, Rosenberg N, Seligsohn U, Inbal A. Seven novel mutations in the Factor XIII A-subunit gene causing hereditary Factor XIII deficiency in ten unrelated families. *J Thromb Haemost* 2:1790-7, 2004.
 78. Dardik R, Loscalzo J, Eskaraev R, Inbal A. Molecular mechanisms underlying the proangiogenic effect of factor XIII (FXIII). *Arterioscler Thromb Vasc Biol* 25:526-532, 2005.
 79. Amir Inbal, Aharon Lubetsky, Tanya Karp, David Castel, Aviv Shaish, Gerhardt Dickneite, Laszlo Modis, Laszlo Muszbek and Aida Inbal. Impaired wound healing in factor XIII deficient mice. *Thromb Haemost* 94:432-437, 2005.
 80. Dardik R, Loscalzo J, Inbal A. Factor XIII and angiogenesis. *J Thromb Hemost* 4:19-25, 2005.
 81. Rima Dardik, Jonathan Leor, David Castel, Ginette Schiby, Aviv Shaish, Gerhardt Dickneite, Joseph Loscalzo, and Aida Inbal. Evaluation of pro-angiogenic activity of factor XIII (FXIII) in murine models of heterotopic heart allograft and FXIII-deficient mice. *Thromb Haemost*, 95:546-50, 2006.

INBAL AIDA, M.D.**15.11.09**

82. Alex Vysokovsky, Nurit Rosenberg, Rima Dardik, Uri Seligsohn, Aida Inbal. Effect of four missense mutations in the factor XIII A-subunit gene on protein stability: studies with recombinant proteins. *Blood Coagul Fibrinol* 17:125-130, 2006.
83. Rima Dardik and Aida Inbal. Complex formation between tissue transglutaminase II (tTG) and Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2): Proposed mechanism for modulation of endothelial cell response to VEGF. *Experimental Cell Research*, 312:2973-82, 2006
84. Dolitzky Mordechai, Inbal Aida, Weiss A, Segal Y, Brenner Benjamin, Carp Howard. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. *Fertil Steril*, 86:362-6, 2006
85. Tecuceanu Noa, Rima Dardik, Ester Rabizada, Pia Raanani, Aida Inbal. A family with Hereditary Thrombocythemia and normal genes for thrombopoietin and c-Mpl. *Br J Haematol* 135:348-51,2006
86. Inbal A, Dardik R. Role of coagulation factor XIII (FXIII) in angiogenesis and tissue repair. *Pathophysiol Haemost Thromb*. 2006;35 :162-165
87. Rima Dardik, Tanya Krapp, Ester Rosenthal, Joseph Loscalzo, Aida Inbal. Effect of FXIII on monocyte and fibroblast function. *Cellular Physiology and Biochemistry* 19: 113-120, 2007
88. Uri Seligsohn, Ariella Zivelin and Aida Inbal. Inherited deficiencies of coagulation factors II, V, VII, X, XI, and XIII and combined deficiencies of factors V and VIII and of the vitamin K-dependent factors. In: *Williams Hematology*, 7th Edition, 2006, pp. 1887-1908.
89. Aida Inbal and Howard Carp. Defects in coagulation factors leading to recurrent pregnancy loss. In: *Recurrent Pregnancy Loss, Causes, Controversies and Treatment*. Publishers: Informa Healthcare. Ed. HJA Carp, 2007, pp: 127-138
90. Hashemi Soteh SM, John Anson, Aida Inbal, Ian R Peake, Ann C Goodeve. Re-evaluation of three Israeli families initially diagnosed with type 1 von Willebrand disease in light of the ISTH update on von Willebrand factor pathophysiology and classification. *Haemophilia*_1-4, 2008 (I.F 1.947; rank: 37 of 63)
91. Tarasenko N, Nudelman A, Tarasenko I, Entin-Meer M, Hass-Kogan D, Inbal A, Rephaeli A. Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). *Clin Exp Metastasis* 2008; 25:703-16
92. Rare bleeding disorders. Peyvandi F, Cattaneo M, Inbal A, De Moerloose P, Spreafico M. *Haemophilia*. 2008 Jul;14 Suppl 3:202-10. Review.

INBAL AIDA, M.D.**15.11.09**

93. Lahav J, Karniel E, Bagoly Z, SheptovitskyV, Dardik R, Inbal A. Coagulation factor XIII serves as protein disulfide isomerase. *Thromb Haemost* 2009 101: 840-4
94. Clinical cross-reactivity between danaparoid and heparin antibodies successfully managed with bivalirudin. Shapiro M, Cohen J, Inbal A, Singer P. *Isr Med Assoc J.* 2009 Mar;11(3):188-90